MX387317B - Composiciones de peptido y metodos de uso. - Google Patents

Composiciones de peptido y metodos de uso.

Info

Publication number
MX387317B
MX387317B MX2017014075A MX2017014075A MX387317B MX 387317 B MX387317 B MX 387317B MX 2017014075 A MX2017014075 A MX 2017014075A MX 2017014075 A MX2017014075 A MX 2017014075A MX 387317 B MX387317 B MX 387317B
Authority
MX
Mexico
Prior art keywords
methods
peptide compositions
photoreceptors
trail
therewith
Prior art date
Application number
MX2017014075A
Other languages
English (en)
Spanish (es)
Other versions
MX2017014075A (es
Inventor
Alexander J Bridges
Cagri G Besirli
David N Zacks
Ethan Sylvain
Francis X Smith
John K Freshley
Linda L Johnson
William A Hunke
Original Assignee
Onl Therapeutics Inc
Univ Michigan Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onl Therapeutics Inc, Univ Michigan Regents filed Critical Onl Therapeutics Inc
Publication of MX2017014075A publication Critical patent/MX2017014075A/es
Publication of MX387317B publication Critical patent/MX387317B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
MX2017014075A 2015-05-01 2016-04-29 Composiciones de peptido y metodos de uso. MX387317B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562155711P 2015-05-01 2015-05-01
PCT/US2016/030098 WO2016178993A1 (en) 2015-05-01 2016-04-29 Peptide compositions and methods of use

Publications (2)

Publication Number Publication Date
MX2017014075A MX2017014075A (es) 2018-07-06
MX387317B true MX387317B (es) 2025-03-18

Family

ID=57217771

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014075A MX387317B (es) 2015-05-01 2016-04-29 Composiciones de peptido y metodos de uso.

Country Status (21)

Country Link
US (5) US10508134B2 (https=)
EP (3) EP3997981A1 (https=)
JP (2) JP6884755B2 (https=)
KR (2) KR20240046280A (https=)
CN (2) CN113651873B (https=)
AU (1) AU2016258837B2 (https=)
CA (1) CA2984154A1 (https=)
CY (1) CY1124911T1 (https=)
DK (1) DK3288379T3 (https=)
EA (2) EA202090184A3 (https=)
ES (1) ES2906173T3 (https=)
HR (1) HRP20220138T1 (https=)
HU (1) HUE057883T2 (https=)
LT (1) LT3288379T (https=)
MX (1) MX387317B (https=)
PL (1) PL3288379T3 (https=)
PT (1) PT3288379T (https=)
RS (1) RS62866B1 (https=)
SI (1) SI3288379T1 (https=)
SM (1) SMT202200069T1 (https=)
WO (1) WO2016178993A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3288379T (lt) 2015-05-01 2022-02-25 Onl Therapeutics, Inc. Peptidų kompozicijos ir naudojimo būdai
WO2019183246A1 (en) * 2018-03-20 2019-09-26 Onl Therapeutics, Inc. Compositions and methods of fas inhibition
EP3810082A1 (en) * 2018-06-19 2021-04-28 Cella Therapeutics, LLC Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
WO2021127052A1 (en) * 2019-12-18 2021-06-24 Cella Therapeutics, Llc DRUG DELIVERY SYSTEMS COMPRISING A NEUROTROPHIC AGENT, AN APOPTOSIS SIGNALING FRAGMENT INHIBITOR (FAS) OR FAS LIGAND (FASL) INHIBITOR, A TUMOR NECROSIS FACTOR-α (TNF-α) OR TNF RECEPTOR INHIBITOR, A MITOCHONDRIAL PEPTIDE, AN OLIGONUCLEOTIDE, A CHEMOKINE INHIBITOR, OR A CYSTEINE-ASPARTIC PROTEASE INHIBITOR
EP4355349A4 (en) * 2021-06-15 2025-04-16 ONL Therapeutics, Inc. Methods and compositions for treating eye diseases and disorders
AU2022311780A1 (en) * 2021-07-13 2024-02-08 Onl Therapeutics, Inc. Methods and compositions for improving visual function in ocular diseases and disorders
WO2023129766A1 (en) * 2021-12-27 2023-07-06 Onl Therapeutics, Inc. Sfasl for inhibiting rpe cell death and associated disorders
EP4565596A1 (en) * 2022-08-05 2025-06-11 ONL Therapeutics, Inc. Peptide compositions and methods of use
US20260062449A1 (en) * 2022-08-05 2026-03-05 Onl Therapeutics, Inc. Peptide compositions and methods of use
EP4698204A1 (en) * 2023-04-19 2026-02-25 ONL Therapeutics, Inc. Methods and compositions for treating rnfl thinning

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5532123A (en) * 1990-07-11 1996-07-02 New York University Receptor-type phosphotyrosine phosphatase-γ
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
JP3187201B2 (ja) * 1992-05-14 2001-07-11 三共株式会社 Ｃ末端にプロリンアミドを有するペプチドの製法
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
JP3460863B2 (ja) 1993-09-17 2003-10-27 三菱電機株式会社 半導体装置の製造方法
US5714353A (en) 1994-05-24 1998-02-03 Research Corporation Technologies, Inc. Safe vectors for gene therapy
US5527928A (en) 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
US5650096A (en) 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5719131A (en) 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5711964A (en) 1995-06-07 1998-01-27 United States Of America Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6001962A (en) * 1996-11-15 1999-12-14 The Regents Of The University Of California Modified Fas ligands
US7091047B2 (en) * 1997-05-23 2006-08-15 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity
US6363020B1 (en) 1999-12-06 2002-03-26 Virage Logic Corp. Architecture with multi-instance redundancy implementation
US6480428B2 (en) 2000-12-19 2002-11-12 Winbond Electronics Corporation Redundant circuit for memory device
US7459527B2 (en) * 2004-03-31 2008-12-02 Xencor, Inc. BMP-7 variants with improved properties
CA2563691A1 (en) 2004-04-23 2005-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Cell death modulation via antagonists of fasl and fas activation
CA2607608A1 (en) * 2005-05-10 2006-11-16 Alcon, Inc. Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders
WO2007056457A2 (en) * 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
JP2009518308A (ja) * 2005-12-01 2009-05-07 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション アポトーシスを阻害するための化合物及び方法
EP2222696A1 (en) * 2007-12-21 2010-09-01 Stryker Corporation Bmp mutants with decreased susceptibility to noggin
CN102449140B (zh) * 2009-03-03 2014-11-26 密执安大学评议会 抑制光感受器凋亡的方法
CN102365093A (zh) * 2009-03-30 2012-02-29 参天制药株式会社 用于视网膜疾病的预防剂或治疗剂和使用JNK(c-Jun氨基末端激酶)抑制肽预防或治疗视网膜疾病的方法以及所述肽的用途
WO2011017350A2 (en) * 2009-08-04 2011-02-10 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
US8865881B2 (en) 2011-02-22 2014-10-21 California Institute Of Technology Delivery of proteins using adeno-associated virus (AAV) vectors
WO2012170392A2 (en) * 2011-06-06 2012-12-13 Kineta One, Llc Shk-based pharmaceutical compositions and methods of manufacturing and using the same
WO2013106909A1 (en) 2012-01-18 2013-07-25 Governing Council Of The University Of Toronto Novel peptides and methods and uses thereof for preventing retinal disorders
WO2013191352A1 (en) * 2012-06-21 2013-12-27 Hanall Biopharma Co., Ltd. New uses of modified human tumor necrosis factor receptor-1 polypeptide
US20150265679A1 (en) * 2012-11-02 2015-09-24 The United States Of America, As Represented By Secretary, Department Of Health And Human Services Method of reducing adverse effects in a cancer patient undregoing treatment with a mek inhibitor
JP2018510359A (ja) 2015-02-05 2018-04-12 イミューンアレイ ユーエスエイ インコーポレイテッド 脳損傷または神経変性を診断するための方法および組成物
US20190201500A1 (en) 2015-05-01 2019-07-04 Onl Therapeutics, Inc. Compositions and methods of fas inhibition
LT3288379T (lt) 2015-05-01 2022-02-25 Onl Therapeutics, Inc. Peptidų kompozicijos ir naudojimo būdai
CN110177577A (zh) 2016-07-05 2019-08-27 马萨诸塞大学 Sfasl的aav2介导的基因递送作为青光眼的神经保护疗法
JP7009517B2 (ja) 2017-06-21 2022-01-25 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ ｇｐ１２０およびｃｄ３を標的とする多重特異性抗体
WO2019183246A1 (en) 2018-03-20 2019-09-26 Onl Therapeutics, Inc. Compositions and methods of fas inhibition
EP3810082A1 (en) 2018-06-19 2021-04-28 Cella Therapeutics, LLC Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension

Also Published As

Publication number Publication date
US20210094985A1 (en) 2021-04-01
SMT202200069T1 (it) 2022-03-21
EA202090184A2 (ru) 2020-05-31
HRP20220138T1 (hr) 2022-05-27
BR112017023479A2 (pt) 2018-07-24
WO2016178993A1 (en) 2016-11-10
CN107708416B (zh) 2021-06-29
US10508134B2 (en) 2019-12-17
DK3288379T3 (da) 2022-02-07
EP3288379A1 (en) 2018-03-07
EP4623925A3 (en) 2026-02-11
JP6884755B2 (ja) 2021-06-09
JP2018514590A (ja) 2018-06-07
US20230287052A1 (en) 2023-09-14
CN113651873B (zh) 2025-09-02
US20250346631A1 (en) 2025-11-13
US10829518B2 (en) 2020-11-10
US20180291062A1 (en) 2018-10-11
US12258425B2 (en) 2025-03-25
PL3288379T3 (pl) 2022-03-07
KR20240046280A (ko) 2024-04-08
EP3997981A1 (en) 2022-05-18
CN113651873A (zh) 2021-11-16
RS62866B1 (sr) 2022-02-28
CY1124911T1 (el) 2023-01-05
US20200123201A1 (en) 2020-04-23
HK1251979A1 (zh) 2019-05-10
JP2021120400A (ja) 2021-08-19
MX2017014075A (es) 2018-07-06
EA035293B1 (ru) 2020-05-26
AU2016258837A1 (en) 2017-11-09
CA2984154A1 (en) 2016-11-10
HUE057883T2 (hu) 2022-06-28
KR102652804B1 (ko) 2024-04-01
LT3288379T (lt) 2022-02-25
KR20170140383A (ko) 2017-12-20
SI3288379T1 (sl) 2022-06-30
PT3288379T (pt) 2022-02-08
EP3288379B1 (en) 2021-11-03
ES2906173T3 (es) 2022-04-13
US11597749B2 (en) 2023-03-07
EA201792399A1 (ru) 2018-05-31
EP3288379A4 (en) 2018-10-24
CN107708416A (zh) 2018-02-16
EP4623925A2 (en) 2025-10-01
EA202090184A3 (ru) 2020-07-31
AU2016258837B2 (en) 2020-12-03

Similar Documents

Publication Publication Date Title
MX387317B (es) Composiciones de peptido y metodos de uso.
CL2018003142A1 (es) Moduladores de la vía de estrés integrada
MX2018007288A (es) Anticuerpos neutralizantes para el virus de inmunodeficiencia humana.
MX369041B (es) Proteinas quimericas tipo fosfatasa alcalina.
ECSP19015192A (es) Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos
DOP2016000177A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
MX378108B (es) Anticuerpos anti-met y composiciones.
EA201691582A1 (ru) Новые фармацевтические препараты
NI201500131A (es) Virus de la enfermedad de newcastle y usos de los mismos
BR112019001233A2 (pt) formulação farmacêutica e uso da mesma
EA201692512A1 (ru) Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
EP3823641A4 (en) MITOCHONDRIAL AUGMENTATION THERAPY OF EYE DISEASES
MX393803B (es) Derivados de amida como bloqueadores de nav1.7 y nav1.8
CL2016001756A1 (es) Preparación farmacéutica que comprende 0,001-0,003 pv de 6-4-pirazol-1-ilbencilpiridin-3-ilsulfonilaminometilpiridin-2-ilaminoacetato de isopropilo o una sal del mismo uso para el tratamiento o prevención de glaucoma o hipertensión ocular.
IL254617B (en) Improved assays for the potential of retinal pigment epithelium (rpe) cells and photoreceptor progenitors
BR112017004893A2 (pt) composições e métodos para o tratamento de lesões cutâneas pré-cancerosas
MX2016015569A (es) Metodos y composiciones para inmunomodulacion.
ZA201701303B (en) Ocular formulations for drug-delivery and protection of the anterior segment of the eye
CL2020001252A1 (es) Métodos de uso y composiciones que contienen dulaglutida.
PE20160596A1 (es) Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana
UY36540A (es) Anticuerpos monoclonales humanos dotados de fuerte actividad neutralizadora contra los virus herpes simple tipo 1 (hsv-1) y tipo 2 (hsv-2)
GT201600255A (es) Compuestos, composición farmacéutica y su uso para tratar enfermedades neurodegenerativas
EA201501130A1 (ru) Офтальмологическая фармацевтическая композиция
BR112017002206A2 (pt) peptídeo derivado de koc1 e vacina incluindo o mesmo
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.